Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05104476 · ClinicalTrials.gov registry record · Phase 2

A Study of Lu AF82422 in Participants With Multiple System Atrophy

A Phase 2 study of Multiple System Atrophy, sponsored by H. Lundbeck A/S.

Active
Registry status
Phase 2
Development phase
64
Enrollment target
19
Study locations

NCT05104476: Active Phase 2 study of Multiple System Atrophy, sponsored by H. Lundbeck A/S.

NCT05104476 is a Phase 2 study of Multiple System Atrophy that is active but no longer recruiting, run by H. Lundbeck A/S. The registered enrollment target is 64 participants, below the 266-participant average among 30 other Multiple System Atrophy trials with a reported enrollment target (76% lower). The trial reports 19 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05104476, a Phase 2 study of Multiple System Atrophy, is active but no longer recruiting, sponsored by H. Lundbeck A/S.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
64 participants
Enrollment target
19
Study locations

Study Summary

To find out the effect of Lu AF82422 on disease progression in participants with multiple system atrophy.

Primary Outcome

The primary endpoint assessed disease progression by a Bayesian repeated measures model on UMSARS TS. Reported here is the estimated slowing (%) of clinical progression in participants receiving Lu AF82422 relative to those receiving placebo. UMSARS is a combined clinician and patient-reported outcome assessment developed to provide a surrogate measure of disease progression in multiple system atrophy (MSA). UMSARS TS was obtained by the sum of the items from Part I and Part II. Part I assesses

Conditions Studied

Multiple System Atrophy

Interventions

  • DRUG Placebo
  • DRUG Lu AF82422

Study Locations (19)

California

  • The Parkinsons and Movement Disorder Institute - Fountain Valley
  • University of California - San Diego - La Jolla
  • University of California, San Francisco Neurosciences Clinical Research Unit - San Francisco

Pennsylvania

  • Penn State Milton S. Hershey Medical Center - Penn State Hershey Neuroscience Institute (PSHNI) - Hershey
  • University of Pennsylvania - Philadelphia
  • University Of Pittsburgh - Pittsburgh

Florida

  • Parkinson's Disease And Movement Disorder Center Of Boca Raton - Boca Raton
  • University of Florida Norman Fixel Institute for Neurological Diseases - Gainesville

Illinois

  • Rush University Medical Center, Rush University Cancer Center - Chicago
  • Endeavor Health - Glenbrook Hospital - Glenview

New York

  • NYU Langone Health Medical Center - New York
  • Columbia University Medical Center - The Neurological Institute of New York - New York

Colorado

  • CenExel Rocky Mountain Clinical Research, LLC - Englewood

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2021-11-16
Est. Completion 2028-03-07
Phase Phase 2
H. Lundbeck A/S

72 total trials

What the registry record for NCT05104476 still lists

NCT05104476 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 266-participant average among 30 other Multiple System Atrophy trials with a reported enrollment target (76% lower).

The record links to 1 condition, with Multiple System Atrophy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05104476 lists 19 locations in 12 states (California, Pennsylvania, Florida).

Frequently Asked Questions

What is clinical trial NCT05104476 about?

NCT05104476 is a clinical study titled "A Study of Lu AF82422 in Participants With Multiple System Atrophy". To find out the effect of Lu AF82422 on disease progression in participants with multiple system atrophy.

What is the current status of trial NCT05104476?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2021-11-16. Estimated completion is 2028-03-07.

What conditions does trial NCT05104476 study?

This clinical trial studies the following conditions: Multiple System Atrophy.

What interventions are being tested in trial NCT05104476?

The interventions under investigation include: Placebo (DRUG), Lu AF82422 (DRUG).

Who is sponsoring clinical trial NCT05104476?

This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05104476 being conducted?

This trial has 19 study locations across California, Colorado, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple System Atrophy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05104476's enrollment target sits among peer trials

64 17th of 30 higher than 14 of 30 other Multiple System Atrophy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple System Atrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01853631 · 64 participants · Phase 1

    Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

  • NCT03739502 · 64 participants · Phase 2

    A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

  • NCT03739814 · 64 participants · Phase 2

    Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • NCT03866408 · 64 participants · Early Phase 1

    Insulin Regulation of Lipolysis and Lipolysis Proteins

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05104476, the US trial registry maintained by the National Library of Medicine. NCT05104476 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.